PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25609059-4	2015	RESULTS: We confirm that both trabectedin and doxorubicin were able to strongly reduce EWS-FLI1 (both type I and type II) binding to two representative target genes (TGFbetaR2 and CD99), both in vitro and in xenografts.	Trabectedin	30-41	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	91-95	
25609059-5	2015	However, trabectedin, but not doxorubicin, was also able to increase the occupancy of EWS-FLI1 to IGF1R promoters, leading to IGF1R upregulation.	Trabectedin	9-20	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	90-94